Analyzing Orthofix (OFIX) and CryoLife (CRY)

Orthofix (NASDAQ: OFIX) and CryoLife (NYSE:CRY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Valuation and Earnings

How to Become a New Pot Stock Millionaire

This table compares Orthofix and CryoLife’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orthofix $433.82 million 2.50 $6.22 million $1.62 36.33
CryoLife $189.70 million 4.11 $3.70 million $0.40 58.25



Orthofix has higher revenue and earnings than CryoLife. Orthofix is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.8% of Orthofix shares are held by institutional investors. Comparatively, 74.1% of CryoLife shares are held by institutional investors. 5.6% of Orthofix shares are held by company insiders. Comparatively, 4.0% of CryoLife shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Orthofix and CryoLife’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orthofix 1.43% 10.66% 7.93%
CryoLife 1.95% 5.93% 3.55%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Orthofix and CryoLife, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orthofix 0 0 6 0 3.00
CryoLife 0 0 3 0 3.00

Orthofix presently has a consensus price target of $56.90, suggesting a potential downside of 3.33%. CryoLife has a consensus price target of $25.83, suggesting a potential upside of 10.87%. Given CryoLife’s higher probable upside, analysts plainly believe CryoLife is more favorable than Orthofix.

Risk and Volatility

Orthofix has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Summary

Orthofix beats CryoLife on 8 of the 13 factors compared between the two stocks.

Orthofix Company Profile

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

CryoLife Company Profile

CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes BioGlue; BioFoam; On-X products; CardioGenesis cardiac laser therapy; PerClot; PhotoFix, Hemodialysis Reliable Outflow Graft; and ProCol Vascular Bioprosthesis. The Preservation Services segment offers preservation of cardiac and vascular tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Receive News & Ratings for Orthofix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply